Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jan 9, 2024
Deals

Jan. 8 Quick Takes: Novartis taps China-based Argo for RNAi deal

Plus: Venrock unveils $650M fund and more from Calypso, Isomorphic, Bayer, Flagship and Vertex
BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

How rising interest in IL-15 helped six-year-old Calypso close its series A
BioCentury | May 27, 2013
Emerging Company Profile

Calypso: Fistula fix

Merck Serono spinout Calypso developing mAbs to treat Crohn's, celiac
BioCentury | May 20, 2013
Company News

Calypso Biotech, iDD Biotech deal

Items per page:
1 - 6 of 6
Help Center
Username
Request a Demo
Request Training
Ask a Question